In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Idenix Pharmaceuticals, Inc.

http://www.idenix.com/

Latest From Idenix Pharmaceuticals, Inc.

Nine Endocrine And Metabolic Disease Drug Launches To Look Out For In 2022

In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are nine new products for endocrine and metabolic disorders that could make their debuts next year.

Approvals Companies

Santhera Raises CHF45m Ahead Of Duchenne Drug Filing

A mix of equity and debt financing has raised enough to satisfy Santhera's liquidity needs until mid-2022, which will be after the Swiss firm has filed its Duchenne drug vamorolone.

Business Strategies Financing

Attralus Raises $116m To Advance Amyloidosis-Clearing Pipeline

The company intends to use the series B cash to bring the first of its pan-amyloid removal (PAR) therapies into the clinic, while also advancing a diagnostic tool for systemic amyloidosis.

Financing Platform Technologies

Demand For Surgical Heart Valves Projected To Slowly Decline

The market for surgical heart valve replacement devices is projected to steadily decline, as newer, more innovative transcatheter techniques poach customers, according to a new report from Informa’s Meddevicetracker.

Market Intelligence Cardiovascular
See All

Company Information

  • Other Names / Subsidiaries
    • Novirio Pharmaceuticals Limited
UsernamePublicRestriction

Register